The combined overexpression of programmed death-ligand 1 (PD-L1) and Akt in adipose-derived mesenchymal stem cells (AdMSCs) has emerged as a promising strategy for myocardial infarction (MI) therapy. Here, AKT1 is linked to myocardial infarction.